Tiziana Completes Dosing in Phase 2 MS Trial, Awaits Data Readout
Event summary
- Tiziana has dosed the last patient in its Phase 2a INFORM-MS trial for non-active secondary progressive multiple sclerosis (na-SPMS).
- Topline data from the randomized, double-blind, placebo-controlled study is expected in late Q3/early Q4 2026.
- The trial evaluates intranasal foralumab’s safety, tolerability, and efficacy across 48 patients at multiple U.S. clinical sites.
- Primary endpoint measures microglial activation via PET scans, with secondary outcomes including EDSS, quality of life, and fatigue assessments.
The big picture
Tiziana’s Phase 2a trial completion marks a critical step in validating its intranasal foralumab approach for na-SPMS, an underserved patient population. The study’s focus on microglial activation and clinical outcomes aligns with growing interest in targeted immune modulation for neurodegenerative diseases. Success here could expand Tiziana’s pipeline potential beyond MS into other neuroinflammatory conditions.
What we're watching
- Data Readout Impact
- How the topline data in late Q3/early Q4 2026 will influence investor sentiment and potential regulatory pathways.
- Clinical Execution
- Whether Tiziana can sustain momentum in its open-label extension phase following the Phase 2a trial.
- Market Differentiation
- The pace at which intranasal foralumab’s novel delivery mechanism could position it as a competitive alternative in the MS treatment landscape.
Related topics